RECRUITING

Yoga for Treatment of Overactive Bladder in Pediatric Patients

Conditions

Overactive Bladder Overactive Bladder Syndrome Overactive Detrusor bladder overactive detrusor pediatric

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this pilot study is to assess the impact of yoga as a treatment modality in pediatric patients age 8-18 diagnosed with idiopathic overactive bladder as measured by validated questionnaires and urinary biomarkers. The main question it aims to answer is: Does yoga help improve overactive bladder symptoms in this patient population? Participants will take part in a weekly yoga session for a total of 6 weeks with validated questionnaires and urinary samples for biomarkers to be completed at the beginning, middle and end of the study. This study will follow a cross-over study design and patients will receive standard of care while not in the active treatment arm.

Official Title

Yoga for Treatment of Overactive Bladder in Pediatric Patients

Quick Facts

Study Start:2025-02

Study Completion:2025-09

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05895045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:8 Years to 18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* 8-18 years of age * History of non-neurogenic overactive bladder or detrusor overactivity and/or urinary incontinence (ICD 10 codes respectively - N32.81, N39.498) * Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPPA) authorization from the participant or the participant's parent/legal guardian * Minor participant is willing and able to provide assent (as applicable) * Vancouver Dysfunctional Elimination Syndrome\[15\] score of ≥11 and a positive modified bother score within 30 days of consent	* Known or apparent untreated anatomical abnormality of lower urinary tract (i.e. untreated ureterocele) * Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord) * Nerve damage that may impact pelvic floor function * History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin) * Active, untreated UTI at the time of enrollment (UTI undergoing active treatment is allowable) * Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential * Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety

Inclusion Criteria

Exclusion Criteria

* 8-18 years of age
* History of non-neurogenic overactive bladder or detrusor overactivity and/or urinary incontinence (ICD 10 codes respectively - N32.81, N39.498)
* Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPPA) authorization from the participant or the participant's parent/legal guardian
* Minor participant is willing and able to provide assent (as applicable)
* Vancouver Dysfunctional Elimination Syndrome\[15\] score of ≥11 and a positive modified bother score within 30 days of consent

* Known or apparent untreated anatomical abnormality of lower urinary tract (i.e. untreated ureterocele)
* Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord)
* Nerve damage that may impact pelvic floor function
* History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin)
* Active, untreated UTI at the time of enrollment (UTI undergoing active treatment is allowable)
* Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential
* Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety

Contacts and Locations

Study Contact

Rafael Tua-Caraccia, MD

CONTACT

7865546150

rdt25@duke.edu

Jonathan Routh, MD, MPH

CONTACT

(919) 684-6994

jonathan.routh@duke.edu

Study Locations (Sites)

Duke University Hospital

Durham, North Carolina, 27701

United States

Collaborators and Investigators

Sponsor: Duke University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02

Study Completion Date2025-09

Study Record Updates

Study Start Date2025-02

Study Completion Date2025-09

Terms related to this study

Keywords Provided by Researchers

bladder
overactive
detrusor
pediatric

Additional Relevant MeSH Terms

Overactive Bladder
Overactive Bladder Syndrome
Overactive Detrusor